<--- Back to Details
First PageDocument Content
Abdominal pain / Peptic ulcer / Benzimidazoles / Proton pump inhibitors / Pyridines / Sulfoxides / Helicobacter pylori / Periodontitis / Stomach disease / Medicine / Gastroenterology / Health
Abdominal pain
Peptic ulcer
Benzimidazoles
Proton pump inhibitors
Pyridines
Sulfoxides
Helicobacter pylori
Periodontitis
Stomach disease
Medicine
Gastroenterology
Health

A Prospective Study of Periodontal Disease and Risk of Gastric and Duodenal Ulcer in Male Health Professionals

Add to Reading List

Source URL: www.nature.com

Download Document from Source Website

File Size: 270,11 KB

Share Document on Facebook

Similar Documents

ORIGINAL ARTICLE doi:j00271.x NATURAL TRANSFORMATION INCREASES THE RATE OF ADAPTATION IN THE HUMAN PATHOGEN HELICOBACTER PYLORI

ORIGINAL ARTICLE doi:j00271.x NATURAL TRANSFORMATION INCREASES THE RATE OF ADAPTATION IN THE HUMAN PATHOGEN HELICOBACTER PYLORI

DocID: 1sDtT - View Document

Press Release  ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections Munich (Germany), October 28, 2014: ImevaX GmbH, a specialist in vaccines agai

Press Release ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections Munich (Germany), October 28, 2014: ImevaX GmbH, a specialist in vaccines agai

DocID: 1rRrC - View Document

ImmunoCard STAT!® HpSA® HD NEXT GENERATION, HIGH DEFINITION RAPID TEST FROM THE LEADER IN STOOL ANTIGEN TESTING  DEFINITIVE ANSWERS, CONFIDENT RESULTS®

ImmunoCard STAT!® HpSA® HD NEXT GENERATION, HIGH DEFINITION RAPID TEST FROM THE LEADER IN STOOL ANTIGEN TESTING DEFINITIVE ANSWERS, CONFIDENT RESULTS®

DocID: 1rtI8 - View Document

Press Release  ImevaX welcomes KfW to investor syndicate in second closing of Series A financing Munich (Germany), March 02, 2015: ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, e

Press Release ImevaX welcomes KfW to investor syndicate in second closing of Series A financing Munich (Germany), March 02, 2015: ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, e

DocID: 1rjwj - View Document

JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, GERMANY Research Centre for Infectious Diseases (ZINF) PhD STUDENT Position “Virulence factors and regulators required during infections with the food-borne pathogen Campyloba

JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, GERMANY Research Centre for Infectious Diseases (ZINF) PhD STUDENT Position “Virulence factors and regulators required during infections with the food-borne pathogen Campyloba

DocID: 1r4bs - View Document